FERO Foundation: driving advanced molecular diagnostics against cancer

Co-led by VHIO’s Director, Josep Tabernero in collaboration with Ana Vivancos, Paolo Nuciforo, and Rodrigo Dienstmann, Principal Investigators of our Cancer Genomics, Molecular Oncology, and Oncology Data Science (ODysSey) Groups, respectively, our Advanced Molecular Diagnostics Program (DIAMAV), is powered by the essential support received from one of our patrons, the FERO Foundation. This program seeks to advance molecular profiling in patients in order to more effectively match personalized treatment strategies based on the genomic or pathologic profile of each individual patient and the molecular makeup of their disease.

It is thanks to the backing received from FERO that VHIO has both established itself as a reference in prescreening and oncogenomics in Europe, and continues to extend its enabling technologies and platforms to an increasing number of individuals. More specifically, driven by VHIO’s Prescreening Program which also counts on the expertise of Rodrigo Dienstmann and his Oncology Data Science (ODysSey) team, and Elena Garralda, Principal Investigator of Early Clinical Drug Development, molecular profiling is performed in over 1500 patients each year.

Our researchers and clinical investigators identify specific molecular risk factors and better predict the potential efficacy of specific agents tailored to each particular tumor. Additionally, this knowledge better guides our multidisciplinary teams to assess and establish patients’ suitability for inclusion in early phase clinical trials led by VHIO’s Research Unit for Molecular Therapy of Cancer (UTIM) – “la Caixa”, also headed by Elena Garralda.

Our VHIO-FERO DIAMAV Program enables us to lead one of the few centers in Europe to run such a comprehensive program, ensure that more of our patients can ultimately benefit from our powerful technology programs and approaches, further advance research into the more effective and less invasive tracking of cancer by liquid biopsy, as well as develop cancer diagnostics for the early detection of disease.

 

VHIO’s prowess in prescreening and insights driven through oncogenomics and cancer diagnostics.

 

 


For more information about our Advanced Molecular Diagnostics Program (DIAMAV), contact: Amanda Wren, Director of Communications at VHIO: awren@vhio.net.